Document is current
Any future updates will be listed below
-
Authors
Knight, Tristan E.
Ahn, Kwang Woo
Hebert, Kyle M.
Atshan, Rasha
Wall, Donna A.
Chiengthong, Kanhatai
Lund, Troy C. https://orcid.org/0000-0001-9174-8919
Prestidge, Tim https://orcid.org/0000-0003-4078-5001
Rangarajan, Hemalatha G. https://orcid.org/0000-0003-3371-2920
Dvorak, Christopher C. https://orcid.org/0000-0002-6146-3952
Auletta, Jeffery J.
Kent, Michael https://orcid.org/0000-0003-1247-4900
Hashem, Hasan https://orcid.org/0000-0002-4681-4726
Talano, Julie-An
Rotz, Seth J. https://orcid.org/0000-0003-2896-1113
Fraint, Ellen https://orcid.org/0000-0001-5548-0206
Myers, Kasiani C. https://orcid.org/0000-0002-5528-4405
Leung, Wing
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Bhatt, Neel S. https://orcid.org/0000-0003-2033-1125
Driscoll, Timothy A.
Yu, Lolie C.
Schultz, Kirk R. https://orcid.org/0000-0002-0001-6438
Qayed, Muna
Broglie, Larisa https://orcid.org/0000-0002-1674-048X
Eapen, Mary
Yanik, Gregory A.
- License Information
-
More Information
Article History
Received: 2 May 2023
Revised: 15 August 2023
Accepted: 17 August 2023
First Online: 4 September 2023
Competing interests
: No funding was secured specifically for this project. Dr. Knight reports partial salary support from Hold’Em for Life Oncology Fellowship, Garron Family Cancer Center Research Fellowship, and BMO Financial Group Oncology Fellowship. Dr. Wall reports steering committee participation for CRISPR/Vertex Pharmaceuticals and Editas Medicine; acting as a study advisor for CRISPR/Vertex Pharmaceuticals and Editas Medicine; acting as a clinical trial site-PI for CRISPR Therapeutics, Vertex Pharmaceuticals, and Novartis; and research funding from CRISPR Therapeutics, Vertex Pharmaceuticals, and Novartis. Dr. Rangarajan reports serving as the BMT Medical Monitor for NMDP (no financial reimbursements); and having served as honorary consultant for Medexus. Dr. Dvorak reports consulting for Jazz Pharma, and Alexion Inc. Dr. Auletta reports employment with National Marrow Donor Program (NMDP); and advisory council participation for Ascella Health. Dr. Talano reports research funding from Miltenyi. Dr. Rotz reports acting as a resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT) (employment). Dr. Myers reports research funding for an investigator initiated clinical trial from Incyte and sponsored research from Elixirgen Therapeutics. Dr. Sharma reports consulting for Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, and Sangamo Therapeutics; research funding from CRISPR Therapeutics. Clinical Trial site-PI: CRISPR Therapeutics, Vertex Pharmaceuticals, Novartis Pharmaceuticals, Magenta Therapeutics, Beam Therapeutics, Honoraria: Vindico Medical Education. Dr. Qayed reports honoraria from Vertex and Novartis.
